Comorbidities Predict Inferior Outcomes in Chronic Lymphocytic Leukemia Treated With Ibrutinib

Cancer - United States
doi 10.1002/cncr.31554
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Beyond Ibrutinib Resistance in Chronic Lymphocytic Leukemia

Cancer therapy & Oncology International Journal
2017English

Anticoagulant Therapy in Patients With Chronic Lymphocytic Leukemia Receiving Ibrutinib

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Arresting the Inflammatory Drive of Chronic Lymphocytic Leukemia With Ibrutinib

Clinical Cancer Research
Cancer ResearchOncology
2016English

Amebic Encephalitis in a Patient With Chronic Lymphocytic Leukemia on Ibrutinib Therapy

Case Reports in Hematology
2018English

Addition of Venetoclax at Time of Progression in Ibrutinib‐treated Patients With Chronic Lymphocytic Leukemia: Combination Therapy to Prevent Ibrutinib Flare

American Journal of Hematology
Hematology
2019English

Experience With Ibrutinib in Patients With Refractory and Recurrent B-Cell Chronic Lymphocytic Leukemia

Medical Council
2017English

Successful Treatment of Chronic Lymphocytic Leukemia Mutlifocal Central Nervous System Involvement With Ibrutinib

Turkish Journal of Haematology
Hematology
2018English

Management of Patients With Chronic Lymphocytic Leukemia Treated With Lenalidomide

Clinical Journal of Oncology Nursing
Oncology
2010English

DNA Methylation Profiles in Chronic Lymphocytic Leukemia Patients Treated With Chemoimmunotherapy

Clinical Epigenetics
GeneticsDevelopmental BiologyMolecular Biology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy